FR11C0053I2 - Molecules ctla4 mutantes solubles et leurs utilisations - Google Patents

Molecules ctla4 mutantes solubles et leurs utilisations

Info

Publication number
FR11C0053I2
FR11C0053I2 FR11C0053C FR11C0053C FR11C0053I2 FR 11C0053 I2 FR11C0053 I2 FR 11C0053I2 FR 11C0053 C FR11C0053 C FR 11C0053C FR 11C0053 C FR11C0053 C FR 11C0053C FR 11C0053 I2 FR11C0053 I2 FR 11C0053I2
Authority
FR
France
Prior art keywords
ctla4 molecules
soluble mutant
mutant ctla4
soluble
molecules
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR11C0053C
Other languages
English (en)
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of FR11C0053I1 publication Critical patent/FR11C0053I1/fr
Application granted granted Critical
Publication of FR11C0053I2 publication Critical patent/FR11C0053I2/fr
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
FR11C0053C 2000-05-26 2011-12-07 Molecules ctla4 mutantes solubles et leurs utilisations Active FR11C0053I2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US57992700A 2000-05-26 2000-05-26
US21406500P 2000-06-26 2000-06-26
PCT/US2001/017139 WO2001092337A2 (en) 2000-05-26 2001-05-23 Soluble ctla4 mutant molecules and uses thereof

Publications (2)

Publication Number Publication Date
FR11C0053I1 FR11C0053I1 (cs) 2012-01-13
FR11C0053I2 true FR11C0053I2 (fr) 2013-01-11

Family

ID=26908652

Family Applications (1)

Application Number Title Priority Date Filing Date
FR11C0053C Active FR11C0053I2 (fr) 2000-05-26 2011-12-07 Molecules ctla4 mutantes solubles et leurs utilisations

Country Status (41)

Country Link
EP (3) EP3029062A1 (cs)
JP (1) JP4328525B2 (cs)
KR (2) KR100889887B1 (cs)
CN (2) CN1309735C (cs)
AR (1) AR031699A1 (cs)
AT (1) ATE271066T1 (cs)
AU (2) AU2001263466C1 (cs)
BE (1) BE2011C041I2 (cs)
BR (1) BRPI0111191B8 (cs)
CA (1) CA2409748C (cs)
CY (2) CY2011019I1 (cs)
CZ (1) CZ304451B6 (cs)
DE (2) DE60104282T2 (cs)
DK (1) DK1248802T3 (cs)
EC (1) ECSP024365A (cs)
EE (2) EE05557B1 (cs)
EG (1) EG24459A (cs)
ES (2) ES2225549T3 (cs)
FR (1) FR11C0053I2 (cs)
GE (1) GEP20053658B (cs)
HK (1) HK1048126B (cs)
HU (2) HU228137B1 (cs)
IL (1) IL152315A (cs)
LT (1) LT5133B (cs)
LU (1) LU91902I2 (cs)
LV (1) LV12994B (cs)
MX (1) MXPA02011534A (cs)
MY (1) MY136113A (cs)
NO (2) NO330797B1 (cs)
PE (1) PE20011338A1 (cs)
PL (1) PL206267B1 (cs)
PT (1) PT1248802E (cs)
RU (1) RU2283847C2 (cs)
SI (1) SI1248802T1 (cs)
SK (1) SK288131B6 (cs)
TR (1) TR200402703T4 (cs)
TW (2) TWI314933B (cs)
UA (1) UA87432C2 (cs)
UY (1) UY26723A1 (cs)
WO (1) WO2001092337A2 (cs)
ZA (1) ZA200208944B (cs)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6887471B1 (en) 1991-06-27 2005-05-03 Bristol-Myers Squibb Company Method to inhibit T cell interactions with soluble B7
US7094874B2 (en) 2000-05-26 2006-08-22 Bristol-Myers Squibb Co. Soluble CTLA4 mutant molecules
US20040022787A1 (en) 2000-07-03 2004-02-05 Robert Cohen Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID
ES2667203T3 (es) * 2000-07-03 2018-05-10 Bristol-Myers Squibb Company Usos de moléculas mutantes de CTL4 solubles
DK1397153T3 (da) 2001-05-23 2008-05-26 Bristol Myers Squibb Co Fremgangsmåde til beskyttelse af allogent ö-celle-transplantat ved anvendelse af oplöselige CTLA4-mutantmolekyler
CA2482042A1 (en) * 2002-04-19 2003-10-30 Bristol-Myers Squibb Company Methods for treating an autoimmune disease using a soluble ctla4 molecule and a dmard or nsaid
DE10232697A1 (de) * 2002-07-15 2004-02-05 Universitätsklinikum Charité, Medizinische Fakultät der Humboldt-Universität zu Berlin Verwendung von CD152 zur Behandlung von Autoimmunkrankheiten und Entzündungen
EP1575998A4 (en) 2002-12-23 2007-07-25 Bristol Myers Squibb Co PROCESS FOR CULTIVATING MAMMALIAN CELLS FOR PROTEIN PRODUCTION
ATE488600T1 (de) * 2002-12-23 2010-12-15 Bristol Myers Squibb Co Produktqualitätsverbesserung in säugerzellkulturverfahrenzur proteinproduktion
MXPA05007019A (es) 2002-12-30 2005-08-18 Amgen Inc Terapia de combinacion con factores co-estimuladores.
EP1684791A4 (en) 2003-10-27 2009-07-01 Amgen Inc COMPOSITIONS AND METHODS FOR MODULATION OF IMMUNE REACTION TO AN IMMUNOGENIC THERAPEUTIC AGENT
AR058568A1 (es) 2005-12-20 2008-02-13 Bristol Myers Squibb Co Metodos para producir una composicion con moleculas ctla4-ig a partir de un medio de cultivo
PT2253644E (pt) 2005-12-20 2014-01-23 Bristol Myers Squibb Co Composições e métodos para a produção de uma composição
US7510844B2 (en) 2006-01-24 2009-03-31 Bristol-Myers Squibb Company CD86 and CD80 receptor competition assays
WO2008005290A2 (en) 2006-06-29 2008-01-10 The Trustees Of Columbia University In The City Of New York Methods for testing anti-thrombotic agents
GB0620934D0 (en) 2006-10-20 2006-11-29 Cambridge Antibody Tech Protein variants
EP2716657A3 (en) 2006-12-20 2014-10-08 Mmrglobal, Inc. Antibodies and methods for making and using them
MX2010004883A (es) 2007-11-01 2010-11-10 Perseid Therapeutics Llc Polipeptidos y acidos nucleicos inmunosupresores.
AU2009298131B2 (en) * 2008-10-02 2016-07-14 Aptevo Research And Development Llc CD86 antagonist multi-target binding proteins
US9540426B2 (en) 2009-10-06 2017-01-10 Bristol-Myers Squibb Company Mammalian cell culture processes for protein production
CN106432474A (zh) * 2010-03-12 2017-02-22 艾伯维生物医疗股份有限公司 Ctla4蛋白和其用途
CA2827492A1 (en) 2011-02-23 2012-08-30 Amgen Inc. Cell culture media for uvc exposure and methods related thereto
WO2013010537A1 (en) 2011-07-20 2013-01-24 Aarhus Universitet Method of treating morphea
US9758566B2 (en) 2012-03-29 2017-09-12 The General Hospital Corporation Recombinant cytotoxic T-lymphocyte-associated protein 4 (CTLA4)
JP6228971B2 (ja) * 2012-05-11 2017-11-08 メディミューン，エルエルシー Ｃｔｌａ−４バリアント
US8735359B2 (en) 2012-05-24 2014-05-27 Orban Biotech Llc Combinations of modalities for the treatment of diabetes
CA2877986A1 (en) * 2012-06-27 2014-01-03 Orban Biotech Llc Ctla4 fusion proteins for the treatment of diabetes
US20140112958A1 (en) 2012-10-24 2014-04-24 Mwm Biomodels Gmbh Pancreatic islets of transgenic LEA29Y animals for treating diabetes
CN104740608A (zh) * 2013-12-30 2015-07-01 上海中信国健药业股份有限公司 可溶性ctla4分子用于制备治疗类风湿性关节炎药物的用途
AU2014376225C1 (en) 2014-01-13 2025-06-05 Amgen Inc. Regulating ornithine metabolism to manipulate the high mannose glycoform content of recombinant proteins
GB2523399B (en) 2014-02-25 2019-03-13 Orban Tihamer A composition comprising ten overlapping peptide fragments of the entire preproinsulin sequence
WO2015188009A1 (en) 2014-06-04 2015-12-10 Amgen Inc. Methods for harvesting mammalian cell cultures
KR102623965B1 (ko) 2014-12-01 2024-01-11 암젠 인크 당단백질의 글리칸 함량 수준을 조작하는 방법
WO2016130734A1 (en) 2015-02-11 2016-08-18 Bristol-Myers Squibb Company Use of phenolic antioxidants in cell culture for the production of proteins
PL3283508T3 (pl) 2015-04-17 2021-10-11 Alpine Immune Sciences, Inc. Białka immunomodulacyjne o dostrajalnym powinowactwie
EP3702470A3 (en) 2015-09-09 2020-10-07 The Trustees of Columbia University in the City of New York Reduction of er-mam-localized app-c99 and methods of treating alzheimer's disease
EP3374493A1 (en) 2015-11-09 2018-09-19 Bristol-Myers Squibb Company Methods to manipulate quality attributes of polypeptides produced in cho cells
US11261233B2 (en) * 2016-09-19 2022-03-01 OncoC4, Inc. CD80 and CD86 binding protein compositions and uses thereof
CN107987153A (zh) * 2016-10-27 2018-05-04 广东香雪精准医疗技术有限公司 高亲和力的可溶性pd-1分子
CN111031790A (zh) 2017-04-20 2020-04-17 E开创生物技术股份有限公司 产生基因修改的动物的方法
KR102813968B1 (ko) 2017-10-10 2025-05-29 알파인 이뮨 사이언시즈, 인코포레이티드 Ctla-4 변이체 면역조절 단백질 및 이의 용도
BR112020013236A2 (pt) 2018-01-03 2020-12-01 Alpine Immune Sciences, Inc. proteínas imunomoduladoras de múltiplos domínios e métodos de seu uso
CN109453383A (zh) * 2018-11-12 2019-03-12 陈慧慧 免疫检查点的抑制剂在制备治疗青光眼及其他眼部免疫损伤机制相关疾病药物中的应用
JP2022545917A (ja) 2019-08-27 2022-11-01 トニックス ファーマ リミテッド 修飾ｔｆｆ２ポリペプチド
SG11202110964QA (en) 2019-12-06 2021-10-28 Regeneron Pharmacetucals Inc Anti-vegf protein compositions and methods for producing the same
US12103960B2 (en) 2020-05-08 2024-10-01 Regeneron Pharmaceuticals, Inc. VEGF traps and mini-traps and methods for treating ocular disorders and cancer
MX2022016104A (es) 2020-06-18 2023-02-01 Regeneron Pharma Enfoque de peptidos pesados para medir con precision lisina de extremo c-terminal sin procesar.
JP2023537670A (ja) 2020-07-28 2023-09-05 シージェン インコーポレイテッド ポリペプチドを生産するための方法及びシステム
JP2025500887A (ja) 2021-12-16 2025-01-15 ブリストル－マイヤーズ スクイブ カンパニー ウイルス不活化用界面活性剤
EP4486865A2 (en) 2022-03-02 2025-01-08 Regeneron Pharmaceuticals, Inc. Bioreactor for antibody production

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5637481A (en) 1993-02-01 1997-06-10 Bristol-Myers Squibb Company Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
US5851795A (en) * 1991-06-27 1998-12-22 Bristol-Myers Squibb Company Soluble CTLA4 molecules and uses thereof
US5844095A (en) 1991-06-27 1998-12-01 Bristol-Myers Squibb Company CTLA4 Ig fusion proteins
CA2110518C (en) * 1991-06-27 2007-05-22 Peter S. Linsley Ctla4 receptor, fusion proteins containing it and uses thereof
ZA98533B (en) * 1997-01-31 1999-07-22 Bristol Myers Squibb Co Soluble CTLA4 mutant molecules and uses thereof.
JP3521382B2 (ja) * 1997-02-27 2004-04-19 日本たばこ産業株式会社 細胞間接着及びシグナル伝達を媒介する細胞表面分子
GB9809280D0 (en) * 1998-04-30 1998-07-01 Rpms Technology Ltd Immunosupression
JP2003532370A (ja) * 1998-10-07 2003-11-05 ミレニアム・ファーマシューティカルズ・インコーポレイテッド 新規なＴｈ２特異的分子およびその使用方法
ES2667203T3 (es) * 2000-07-03 2018-05-10 Bristol-Myers Squibb Company Usos de moléculas mutantes de CTL4 solubles

Also Published As

Publication number Publication date
TR200402703T4 (tr) 2004-11-22
SI1248802T1 (en) 2005-02-28
NO2011027I2 (cs) 2011-12-15
EP1248802A2 (en) 2002-10-16
BR0111191A (pt) 2004-07-06
EP1248802B9 (en) 2005-05-11
EP3029062A1 (en) 2016-06-08
EP1536234B1 (en) 2016-03-16
ECSP024365A (es) 2003-03-31
KR20030009502A (ko) 2003-01-29
SK15702002A3 (sk) 2004-01-08
AU2001263466B2 (en) 2006-04-27
MY136113A (en) 2008-08-29
HU228137B1 (en) 2012-12-28
PL366231A1 (en) 2005-01-24
BRPI0111191B8 (pt) 2021-05-25
EP1536234A2 (en) 2005-06-01
HUS1300012I1 (hu) 2016-08-29
DK1248802T3 (da) 2004-11-15
PT1248802E (pt) 2004-11-30
IL152315A (en) 2010-04-15
JP4328525B2 (ja) 2009-09-09
BE2011C041I2 (cs) 2020-08-20
HUP0302201A2 (hu) 2003-10-28
PL206267B1 (pl) 2010-07-30
DE60104282D1 (de) 2004-08-19
CZ304451B6 (cs) 2014-05-14
EE05557B1 (et) 2012-08-15
EE05458B1 (et) 2011-08-15
GEP20053658B (en) 2005-11-10
HK1048126A1 (en) 2003-03-21
IL152315A0 (en) 2003-05-29
UY26723A1 (es) 2001-12-28
RU2283847C2 (ru) 2006-09-20
TWI319405B (en) 2010-01-11
TW200906857A (en) 2009-02-16
WO2001092337A3 (en) 2002-05-10
KR100889887B1 (ko) 2009-03-24
NO20025656D0 (no) 2002-11-25
LV12994B (en) 2003-08-20
HK1048126B (en) 2005-03-04
EP1536234A3 (en) 2009-06-03
HUP0302201A3 (en) 2010-01-28
CN1309735C (zh) 2007-04-11
CN1441810A (zh) 2003-09-10
EP1248802B1 (en) 2004-07-14
CA2409748A1 (en) 2001-12-06
NO330797B1 (no) 2011-07-18
EG24459A (en) 2009-07-16
DE122011100063I1 (de) 2012-06-14
HK1071931A1 (en) 2005-08-05
JP2004511213A (ja) 2004-04-15
KR100895134B1 (ko) 2009-05-04
CZ20023892A3 (cs) 2003-09-17
CN101255192A (zh) 2008-09-03
CY2011019I2 (el) 2016-12-14
NO20025656L (no) 2002-11-25
ES2225549T3 (es) 2005-03-16
NO2011027I1 (no) 2012-01-09
DE60104282T2 (de) 2005-10-13
AU2001263466C1 (en) 2006-10-26
MXPA02011534A (es) 2004-08-12
SK288131B6 (sk) 2013-10-02
CA2409748C (en) 2008-09-16
TWI314933B (en) 2009-09-21
LT2002114A (en) 2003-12-29
AU6346601A (en) 2001-12-11
ZA200208944B (en) 2004-02-13
PE20011338A1 (es) 2002-01-13
EE200200659A (et) 2004-06-15
BRPI0111191B1 (pt) 2019-12-31
CY2011019I1 (el) 2016-12-14
FR11C0053I1 (cs) 2012-01-13
LT5133B (lt) 2004-05-25
WO2001092337A2 (en) 2001-12-06
CY1117625T1 (el) 2017-04-26
EE201100050A (et) 2011-10-17
KR20070094019A (ko) 2007-09-19
LU91902I2 (fr) 2012-01-16
ES2571852T3 (es) 2016-05-27
ATE271066T1 (de) 2004-07-15
UA87432C2 (uk) 2009-07-27
AR031699A1 (es) 2003-10-01

Similar Documents

Publication Publication Date Title
FR11C0053I2 (fr) Molecules ctla4 mutantes solubles et leurs utilisations
FR18C0002I2 (fr) Derives bacteriochlorophylles anioniques solubles dans l'eau et leurs utilisations
MA27035A1 (fr) Ligands de recepteurs de 5-ht et leurs utilisations
DE60018835D1 (de) Differentialgehäuse
DE50013828D1 (de) Differenzverstärker
DE60014371D1 (de) Polysaccharidderivat
EP1587482A4 (en) INFLAMMATORY COMPOSITIONS AND ITS USES
EP1562968A4 (en) ANTI-IL-6 ANTIBODIES, COMPOSITIONS, METHODS, AND APPLICATIONS
FR2785543B1 (fr) Exosomes modifies et utilisations
EP1539754A4 (en) BENZIMIDAZOCHINOLINONE AND ITS USE
AU2001263466A1 (en) Soluble CTLA4 mutant molecules and uses thereof
EP1327713A4 (en) MULTILAYER LIQUID AND ITS USE
DE69934629D1 (de) Differenzverstärker
EP1538907A4 (en) FTSZ-HEMMER AND ITS USE
EP1562627A4 (en) CORTICOSTEROID CONJUGATES AND ITS USES
DE60121132D1 (de) Vollsperrendes momentabhängiges differential
FR2819410B1 (fr) Composition cosmetique irisee et ses utilisations
DE50000507D1 (de) Ausgleichsgetriebe
ITMI20000280A0 (it) Differenziale
EP1699485A4 (en) ANTI-HYDROLYSATE ANTIBODIES AND ITS USES
DE60045802D1 (de) Differenzverstärkerschaltung
DE60109480D1 (de) Panelverbinder
FR2819411B1 (fr) Composition cosmetique irisee et ses utilisations
EP1263767A4 (en) BETA NETRIN AND ITS USE
ATE289720T1 (de) Transaktionszertifizierung